Lascufloxacin hydrochloride to treat bacterial infection
Copyright 2020 Clarivate Analytics..
Lascufloxacin hydrochloride (AM-1977) is a novel 8-methoxy fluoroquinolone antibacterial agent with a unique pharmacophore at the 1st and 7th positions of the quinoline nucleus developed by Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan). It has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for treatment of respiratory tract and ear, nose and throat infections including community-acquired pneumonia and otorhinolaryngological infections, and shows great promise against fluoroquinolone-resistant strains of major pathogens which infect the respiratory tract. It is suitable for treating infections caused by Staphylococcus, Streptococcus, Pneumococcus, Moraxella (Branhamella) catarrhalis, Klebsiella, Enterobacter, Haemophilus influenzae, Legionella pneumophila, Prevotella and Mycoplasma pneumoniae that are sensitive to this drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 56(2020), 6 vom: 25. Juni, Seite 365-376 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thakare, R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 16.09.2020 Date Revised 16.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2020.56.6.3137167 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311043992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311043992 | ||
| 003 | DE-627 | ||
| 005 | 20231225141415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2020.56.6.3137167 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM311043992 | ||
| 035 | |a (NLM)32525135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thakare, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lascufloxacin hydrochloride to treat bacterial infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2020 | ||
| 500 | |a Date Revised 16.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2020 Clarivate Analytics. | ||
| 520 | |a Lascufloxacin hydrochloride (AM-1977) is a novel 8-methoxy fluoroquinolone antibacterial agent with a unique pharmacophore at the 1st and 7th positions of the quinoline nucleus developed by Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan). It has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for treatment of respiratory tract and ear, nose and throat infections including community-acquired pneumonia and otorhinolaryngological infections, and shows great promise against fluoroquinolone-resistant strains of major pathogens which infect the respiratory tract. It is suitable for treating infections caused by Staphylococcus, Streptococcus, Pneumococcus, Moraxella (Branhamella) catarrhalis, Klebsiella, Enterobacter, Haemophilus influenzae, Legionella pneumophila, Prevotella and Mycoplasma pneumoniae that are sensitive to this drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-infective therapy | |
| 650 | 4 | |a Antibacterial drugs | |
| 650 | 4 | |a Fluoroquinolones | |
| 650 | 4 | |a Gram-positive bacteria | |
| 650 | 4 | |a Lascufloxacin hydrochloride | |
| 650 | 4 | |a Quinolone-resistant strains | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Fluoroquinolones |2 NLM | |
| 650 | 7 | |a lascufloxacin |2 NLM | |
| 700 | 1 | |a Singh, S |e verfasserin |4 aut | |
| 700 | 1 | |a Dasgupta, A |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 56(2020), 6 vom: 25. Juni, Seite 365-376 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2020 |g number:6 |g day:25 |g month:06 |g pages:365-376 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2020.56.6.3137167 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2020 |e 6 |b 25 |c 06 |h 365-376 | ||